Trial Profile
A randomised phase II study of two dose schedules of PI-88 in combination with docetaxel in patients with androgen-independent prostate cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Muparfostat (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms ProPIT
- Sponsors Progen Pharmaceuticals Limited
- 08 May 2009 New source identified and integrated (Australian New Zealand Clinical Trials Registry).
- 21 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Feb 2008 Interim results were reported at the 2008 ASCO Genitourinary Cancer Symposium, as reported by a Progen Pharmaceuticals media release.